CTX310 for High Cholesterol

Recruiting at 17 trial locations

Overseen By Clinical Trials

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: CRISPR Therapeutics AG

Must not be taking: Hepatocyte-targeted siRNA

Disqualifiers: Liver disease, Kidney dysfunction, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 day

90 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Are You a Good Fit for This Trial?

Inclusion Criteria

I am between 18 and 75 years old.

Able to provide written informed consent

My cholesterol did not improve after trying the strongest standard treatments for at least 12 weeks.

Exclusion Criteria

I am currently taking or have recently taken a specific medication.

Participants with familial chylomicronemia syndrome (FCS) with some exceptions

My kidney, heart, blood, or liver function is not normal.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a dose of CTX310 via intravenous (IV) infusion

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months

What Are the Treatments Tested in This Trial?

Interventions

• CTX310

How Is the Trial Designed?

Group I: CTX310 Experimental Treatment 1 Intervention

Subjects will receive an intravenous (IV) infusion.

Who Is Running the Clinical Trial?

CRISPR Therapeutics AG

Lead Sponsor

Trials

9

Recruited

640+